Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female 11-25 years old healthy subjects;~* who had received the primary immunization with a vaccine containing DT or Tdap antigens and a T, Td, or Tdap booster injection at least 5 years prior to study entry~Exclusion Criteria:~* previous ascertained or suspected disease caused by N. meningitidis~* previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* serious acute, chronic or progressive disease~* history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component~* known or suspected impairment/alteration of immune function, either congenital or acquired

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Tdap + MenACWY-CRM (Type: EXPERIMENTAL): Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
- Tdap + saline (Type: EXPERIMENTAL): Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
- MenACWY-CRM + saline (Type: EXPERIMENTAL): Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms

Based on this trial design, predict the completion outcome and termination type (if applicable).